Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Belite Bio Inc BLTE

Healthcare Biotechnology
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic... see more

Recent & Breaking News (NDAQ:BLTE)

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

GlobeNewswire May 1, 2024

Belite Bio Announces $25 Million Registered Direct Offering

GlobeNewswire April 25, 2024

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

GlobeNewswire March 22, 2024

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

GlobeNewswire March 11, 2024

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 11, 2024

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire March 6, 2024

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire March 4, 2024

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 7, 2024

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

GlobeNewswire November 30, 2023

Belite Bio to Participate in the BTIG Ophthalmology Day

GlobeNewswire November 20, 2023

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

GlobeNewswire November 13, 2023

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

GlobeNewswire November 6, 2023

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

GlobeNewswire October 27, 2023

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

GlobeNewswire August 8, 2023

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

GlobeNewswire August 4, 2023

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

GlobeNewswire July 27, 2023

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

GlobeNewswire July 24, 2023

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

GlobeNewswire May 30, 2023

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

GlobeNewswire May 30, 2023